Imidlertid var størstedelen af de hyppigst forekommende bivirkninger milde til moderate de indtrådte typisk i starten af behandlingen, og de fleste bivirkninger aftog ved fortsat behandling.
However, the majority of common adverse reactions were mild to moderate, they usually started early in therapy, and most tended to subside even as therapy was continued.